Abstract
The genetic polymorphism of drug-metabolizing enzymes has a major influence on the fate of xenobiotic substances, whether as drugs or absorbed from the environment. Our understanding of this polymorphism is important in order to evaluate the genetic predisposition for exposure-related risks and, in the future, to develop individualized drug therapy. Cytochrome P450 enzymes play a central role in the metabolism of many drugs, chemicals, and carcinogens. Differences in the activity of these enzymes are responsible for the inter-individual variability in drug response and toxicity (Bertilsson, 1995). Of the cytochrome P450 enzymes, the isoform CYP2C19 is of particular interest because of its high inter-individual and inter-racial differences (Goldstein et al., 1997; Kaneko et al., 1999; Griese et al., 2001).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adedoyin, A., Prakash, C., O’Shea, D., Blair, I.A., and Wilkinson, G.R., 1994, Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4: 27–38.
Andersson, T., Cederberg, C., Edvardsson, G., Heggelund, A., and Lundborg, P., 1990, Effect of omeprazole on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47: 79–85.
Andersson, T., Miners, J.O., Veronese, M.E., Tassaneeyakul, W., Meyer, U.A., and Birkett, D.J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36: 521–530.
Bertilsson, L., 1995, Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet. 29: 192–209.
Bertilsson, L., Henthorn, T.K., Sanz, E., Tybring, G., Säwe, J., and Villén, T., 1989, Importance of genetic factors in the regulation of diazepam metabolism: relationship to Smephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45: 348–355.
Capelli, C., Wilson, J.F., Richards, M., Stumpf, M.P.H., Gratrix, F., Oppenheimer, S., et al., 2001, A predominantly indigenous paternal heritage for the Austronesian-speaking peoples of insular Southeast Asia and Oceanic. Am. J. Hum. Genet. 68: 432–443.
De Morais, S.M.F., Wilkilson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K., and Goldstein, J.A., 1994, The major genetic defect responsible for the polymorphisme of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15419–15422.
Ferguson, R.J., De Morais, S.M., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G.R., Sarich, T.C., Wright, J.M., Dayer, P., and Goldstein, J.A., 1998, A new genetic defect in human CYP2C 19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284: 356–361.
Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., et al., 1998, Effect of genetic differences in omeprazole metabolism on cure rate for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 29 :1027–1030.
Goldstein, J.A., and Blaisdell, J., 1996, Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 272: 210–217.
Goldstein, J.A., Ishizaki, T., Chiba, K., de Morais, S.M.F., Bell, D., Krahn, P.M., and Evans, D.A.P., 1997, Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7: 59–64.
Griese, E.U., Ilett, K.F., Kitteringham, N.R., Eichelbaum, M., Powell, H., Spargo, R.M., et al., 2001, Allele and genotype frequencies and polymorphic cytochromes P450 2D6, 2C19 and 2E1 in Aborigines from Western Australia. Pharmacogenetics 11 : 69–76.
Herrlin, K., Massele, A.Y., Jande, M., Alm, C., Tybring, G., Abdi, Y.A., et al., 1998, Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64 :391–401.
Ibeanu, G.C., Goldstein, J.A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B.I., and Blaisdell J., 1998, Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286: 1490–1495.
Ibeanu, G.C., Blaisdell, J., Ferguson, R.J., Ghanayem, B.I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G.R., Dayer P, and Goldstein, J.A., 1999, A novel transversionin the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290: 635–640.
Kaneko, A., Lum, J.K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., et al., 1999, High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific Islands. Pharmacogenetics 9: 581–590.
Kayser, M., Brauer, S., Weiss, G., Schiefenhovel, W., Underhill, P., and Stoneking, M., 2001, Independent histories of human Y chromosomes from Melanesia and Australia. Am. J. Hum. Genet. 68: 173–190.
Kimura, M., Ieiri, I., Mamiya, K., Urae, A., and Higuchi, S., 1998, Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.Ther. Drug. Monit. 203: 243–247.
Kubota, T., Chiba, K., and Ishizaki, T., 1996, Genotyping of S-mephenytoin 4’-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60: 661–666.
Lum, J.K., and Cann, R.L., 1998, mtDNA and language support a common origin of Micronesians and Polynesians in Island Southeast Asia. Am. J. Phys. Anthropol. 105: 109–119.
Lum, J.K., Cann, R.L., Martinson, J.J., and Jorde, L.B., 1998, Mitochondrial and nuclear genetic relationships among Pacific Island and Asian populations. Am. J. Hum. Genet. 63: 613–624.
Masimirembwa, C., Bertilsson, L., Johansson, I., Hasler, J.A., and Ingelman-Sundberg, M., 1995, Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2CI9) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57: 656–661.
Nielsen, K.K., Flinois, J.P., Beaune, P., and Brosen, K., 1996, The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther. 277: 1659–1664.
Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L., and Ingelman-Sundberg. M., 1996, SMephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6: 521–526.
Poolsup, N., Li, W.P.A., and Knight, T.L., 2000, Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25: 197–220.
Qin, X.P., Xie, H.G., Wang, W., He, N., Huang, S.L., Xu, Z.H., Ou-Yang, D.S., et al., 1999, Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66: 642–646.
Richards, M., Oppenheimer, S., and Sykes, B., 1998, mtDNA suggests Polynesian origins in eastern Indonesia. Am. J. Hum. Genet. 63: 1234–1236.
Richardson, T.H., Griffin, K.J., Jung, F., Raucy, J.L., and Johnson, E.F., 1997, Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch. Biochem. Biophys. 338: 157–164.
Roh, H.K., Dahl, M.L., Johansson, I., Ingelman-Sundberg, M., Cha, Y.N., and Bertilsson, L., 1996, Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6: 441–447.
Romkes, M., Faletto, M.B., Blaisdell, J.A., Raucy, J.L., and Goldstein, J.A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochem. 30: 3247–3255.
Sindrup, S.H., Brosen, K., Hansen, M.G.J., Aaes-Jorgensen, T., Overo, K.F., and Gram, L.F., 1993, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug. Monit. 15: 11–17.
Taniwagara, Y., Aoyama, N., Kita, T., Shirakawa, K., Komada, F., Kasuga, M., and Okumura, K., 1999, CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66: 528–534.
Thomson, R.J.M., Martinson, J.J., Norwich, J.T., Harding, R.M., Clegg, J.B., and Boettcher, B., 1996, An ancient common origin of Aboriginal Australians and New Guinea highlanders is supported by aα-globin haplotypes analysis. Am. J. Hum. Genet. 58: 1017–1024.
Ventakakrishnan, K., Greenblatt, G.J., von Moltke, L.L., Schmider, J., Harmatz J.S., and Shader R.I., 1998, Five distinct human cytochromes mediate amitriptyline Ndemethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 38: 112–121.
Ward, S.A., Walle T., Walle, U.K., Wilkinson G.R., and Branch, R.A., 1989, Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 45: 72–79.
Wright, J.D., Helsby, N.A., and Ward, S.A., 1995, The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br. J. Clin. Pharmacol. 39: 441–444.
Xiao, Z.S., Goldstein, J.A., Xie, H.G., Blaisdell, J., Wang, W., Jiang, C.H., et al., 1997, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281: 604–619.
Yasumori, T., Li, Q.H., Yamazoe, Y., Ueda, M., Tsuzuki, T., and Kato, R., 1994, Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4’-hydroxylation. Pharmacogenetics 4: 323–331.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yusuf, I., Djojosubroto, M.W., Ikawati, R., Lum, K., Kaneko, A., Marzuki, S. (2003). Ethnic and Geographical Distributions of CYP2C19 Alleles in the Populations of Southeast Asia. In: Marzuki, S., Verhoef, J., Snippe, H. (eds) Tropical Diseases. Advances in Experimental Medicine and Biology, vol 531. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0059-9_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-0059-9_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4905-1
Online ISBN: 978-1-4615-0059-9
eBook Packages: Springer Book Archive